AATec Medical and Northway Biotech Announce Partnership to Develop Industrial Production Process for ATL-105 Targeting Lung Diseases
· Partnership established to develop and scale production of ATL-105, a novel recombinant version of alpha-1 antitrypsin · Lead indication is non-CF bronchiectasis; ATL-105 targe
AATec Medical Secures EUR 4 Million to Advance Lead Respiratory Drug Candidate to Clinical Development
Funding from SPRIND and Family Offices accelerates preparation of ATL-105 for clinical development in lead indication non-CF related bronchiectasis by 2026 Munich, Germany – 15.0
AATec Medical Welcomes Professor James Chalmers to Scientific Advisory Board
Leading Expert in Respiratory Medicine Supporting AATec in Product Development in Non-CF Bronchiectasis Munich, Germany – 18.09.2024 – AATec Medical GmbH (AATec), a biotech com
AATec Medical reports significant progress in company’s first year towards unlocking the therapeutic potential of AAT
Major advancements in the development of ATL-105 for the treatment of inflammatory lung diseases: Clinical trial in non-cystic fibrosis bronchiectasis (NCFB) to start in 2025 Pre
AATec Medical starts collaboration with the German Federal Agency for Disruptive Innovation SPRIND for alpha-1 antitrypsin
Project for the preclinical development of ATL-105, a recombinant alpha-1 antitrypsin (AAT)-based drug platform for the treatment of inflammatory diseases, viral infections, and ra
